People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OrphoMed, Inc. | — | Biotechnology | Series B | $24.6M | $864.1M | 2017 |
| Femta Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.7M | $83.7M | 2009 |
Kenneth Widder at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Widder on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Martin | 1 | 11 |
| Art Pappas | 1 | 3 |
| Frank Torti | 1 | 3 |
| Thomas D. Kiley | 1 | 2 |
| Jay Short | 1 | 2 |
| Nikhilesh Singh | 1 | 1 |
| Per Peterson | 1 | 1 |
| Jim Woody | 1 | 1 |
| Nikhilesh Singh, Ph.D. | 1 | 1 |
| Stephen Keane | 1 | 1 |
| Michael D. Chao | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.